Public Company

Cipla to raise Rs 1,500 cr by issue of shares

Drug maker Cipla today said it will raise Rs 1,500 crore from international market by issue of securities. - SC refuses relief to Roche on patent plea against Cipla - Drug to treat swine flu to be available in retail mkt - JB Chemicals gets USFDA nod for its anti-allergic tablets - Cipla gains 3% on capex plan - GSK to launch "promecta" in India by 2009-end - Aurobindo Pharma receives Swissmedic approval for cefepime for injection The shareholders have approved raising Rs 1,500 crore by issuing non-convertible debentures, Foreign Currency Convertible Bonds, American Depository Receipts and Global Depository Receipts, Cipla said in a filing to the Bombay Stock Exchange. The proposal is subjected to necessary regulatory approvals, the filing added. Shares of Cipla today closed at Rs 272.30 on BSE, up 0.91 per cent from the previous close.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Hard times in software
Business Standard / New Delhi November 24, 2009, 0:08 IST
Popular Articles
fast payday loans

Clock makers exit due to high taxes
Faced with a heavy tax burden, the small-scale wall clock makers of Morbi (Gujarat) are diversifying into ceramics, stationery items and retail. Besides, the industry is also losing ground to the metros and cities like Bangalore, where clock manufacturing has started picking up and taxation levels are lower, Morbi players claim.

Riding on the rally
With markets moving up on the disinvestment buzz, Smart Portfolios too registered steady gains last week. It was after a while that all fund managers participated in the markets. While Phani Sekhar and Praveen Panjwani were seen re-building their portfolios, Amar Ambani and Ajay Parmar continued with their churning process.

© Copyright 2009